Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon

Table 1 Outcomes of interferon-based therapy in hemodialysis patients

Author	Number of studies included	Patients (n)	Regimen	SVR	Treatment discontinued for adverse effects	Predictors of SVR
Alavian et al[60]	21	491	IFN α 2a or 2b	39.1%	29.7%	Age < 40
	12	279	PegIFN α 2a or 2b	39.3%	22.6%
Gordon et al[59]	20	459	IFN	41%	26%	Lower HCV RNA non-cirrhotic elevated ALT genotype 1
	3	38	PegIFN	37%	28%
	2	49	PegIFN/RBV	43%-97%
Fabrizi et al[58]	13	539	IFN	1OR of no SVR	1OR dropout	N/A
			(10 studies)	0.081	0.389
			IFN + RBV	(0.029-0.230)	(0.155-0.957)
			(3 studies)

¹This analysis only reported the OR, rather than %SVR and dropout; data support relative benefit of IFN-based therapy on SVR, but do not provide absolute benefit. IFN: Interferon; PegIFN: Pegylated interferon; RBV: Ribavirin; OR: Odds ratio; SVR: Sustained virologic response.